Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/106923
DC FieldValueLanguage
dc.contributor.authorNaranjo Hernández, Antonioen_US
dc.contributor.authorMolina, Amparoen_US
dc.contributor.authorQuevedo, Adriánen_US
dc.contributor.authorRubiño, Francisco J.en_US
dc.contributor.authorSánchez-Alonso, Fernandoen_US
dc.contributor.authorRodríguez-Lozano, Carlosen_US
dc.contributor.authorOjeda, Soledaden_US
dc.date.accessioned2021-04-19T15:22:41Z-
dc.date.available2021-04-19T15:22:41Z-
dc.date.issued2021en_US
dc.identifier.issn1862-3522en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/106923-
dc.description.abstractSummary: We analyzed the long-term persistence of treatment in a FLS. During follow-up, 15.2% of patients had a refracture and 23.8% died. At the 5-year checkup, 74% had started treatment (associated with female sex, previous use of bisphosphonate, and referral to an osteoporosis clinic). Persistence at 1 and 5 years was 70.6% and 46.5%, respectively. Introduction: To analyze the long-term persistence of treatment in a fracture liaison service (FLS). Methods: Patients ≥ 50 years with a fragility fracture attended between 2012 and 2016 who were recommended for treatment to prevent new fractures were included. Baseline data included demographics, type of fracture, previous treatment, and FRAX® items. Five years later, patient records were reviewed and the following data were collected: [1] survival; [2] refracture; [3] initiation of treatment, persistence, and medication possession ratio (MPR) > 80%. Results: We included 888 patients, mean age 75 years, 83% women, and mean follow-up 56 months. During follow-up, 135 patients (15.2%) had a refracture (109 major fractures, 50 hip refractures) and 212 patients died (23.8%); at the 5-year checkup, 657 patients (74%) had started some type of treatment. Factors associated with the start of treatment were female sex (OR 2.10; 95% CI: 1.42–3.11), previous use of bisphosphonate (OR 3.91; 95% CI: 2.23–6.86), and referral to an osteoporosis clinic (OR 1.46; 95% CI: 1.02–2.07). Persistence decreased from 70.6% at 12 months to 46.5% at 60 months. An MPR > 80% was confirmed in 449 patients, 68.3% of whom were under treatment. A total of 521 and 447 patients received treatment for at least 24 and 36 months, respectively (79.3% and 68.0% of those who started treatment). Conclusions: Patients with fragility fractures attended at an FLS showed optimal long-term persistence of treatment. These data can help healthcare managers better calculate the cost-effectiveness of implementing the FLS model.en_US
dc.languageengen_US
dc.relation.ispartofArchives of Osteoporosisen_US
dc.sourceArchives of Osteoporosis [ISSN 1862-3522], v. 16 (1), 60, (Diciembre 2021)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320714 Osteopatologíaen_US
dc.subject.otherAdherenceen_US
dc.subject.otherBisphosphonateen_US
dc.subject.otherFractureen_US
dc.subject.otherFracture Liaison Serviceen_US
dc.subject.otherOsteoporosisen_US
dc.subject.otherPersistenceen_US
dc.titleFracture liaison service model: treatment persistence 5 years lateren_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s11657-021-00925-6en_US
dc.identifier.scopus85103814987-
dc.contributor.authorscopusid7003297397-
dc.contributor.authorscopusid57198189392-
dc.contributor.authorscopusid57222724280-
dc.contributor.authorscopusid57211988115-
dc.contributor.authorscopusid56589016600-
dc.contributor.authorscopusid6603136298-
dc.contributor.authorscopusid57198031414-
dc.identifier.eissn1862-3514-
dc.identifier.issue1-
dc.relation.volume16en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.date.coverdateDiciembre 2021en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,693
dc.description.jcr2,879
dc.description.sjrqQ2
dc.description.jcrqQ2
dc.description.scieSCIE
dc.description.miaricds10,7
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Grupo de investigaciones infecciosas, nutricionales e inflamatorias en pacientes hospitalarios / Study Group on infectious, nutritional and inflammatory diseases in hospitalized patients-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2013-6664-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameNaranjo Hernández, Antonio-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

13
checked on Mar 30, 2025

WEB OF SCIENCETM
Citations

10
checked on Mar 30, 2025

Page view(s)

135
checked on Aug 24, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.